Disclosure of Interests: Marina Magrey Consultant of: MM has received consulting fees from UCB, Novartis, Eli Lilly, Pfizer, and Janssen., Grant/research support from: MM has received research grants from Amgen, Abbvie, Eli Lilly, Pfizer, and UC Pharma.

Manish Jain Consultant of: MJ received consulting fees from Amgen, Abbvie, Eli Lilly, Pfizer, and Novartis., Grant/research support from: MJ received consulting fees from Amgen, Abbvie, Eli Lilly, Pfizer, and UC Pharma.

Dennis McGonagle Speakers bureau: DM is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer., Consultant of: DM is a member of speaker bureaus for AbbVie, Janssen, Novartis, and Pfizer., Grant/research support from: DM received research support from AbbVie, Janssen, Novartis, and Pfizer.

Byron Padilla Shareholder of: BP may hold AbbVie stock or stock options., Employee of: BP is a full-time employee of AbbVie., Cuiyong Yue Shareholder of: CY may hold AbbVie stock or stock options., Employee of: CY is a full-time employee of AbbVie., Erin McDearmon-Blondell Shareholder of: EMB may hold AbbVie stock or stock options., Employee of: EMB is a full-time employee of AbbVie., Tiffany A. Fishman Consultant of: TF has received consulting fees from UCB, Novartis, Eli Lilly, Pfizer, and Janssen., Grant/research support from: TF has received research support from AbbVie, Janssen, Novartis, and Pfizer.

Jayne Stigler Shareholder of: JS may hold AbbVie stock or stock options., Employee of: JS is a full-time employee of AbbVie., RC is a full-time employee of AbbVie., Kersten Reich Consultant of: KR has received consulting fees from AbbVie., Grant/research support from: KR received research support from AbbVie, Janssen, Novartis, and Pfizer.

Nancy Niguidula, DPH, of JB Ashtin. Writing assistance, funded by AbbVie, was provided by Kersten Reich, MPH, as a Research Associate.

The results of the present study demonstrated a higher retention rate in the first-line bDMARDs treatment in comparison with second-line. Female sex and anxiety-depressive disorders may negatively affect drug retention rate.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3829